Yeah, there is clearly a path that is suggested by the patients whenever they refuse to undergo a radical cystectomy after, primarily after a major response, deeper response, almost complete response or near complete response after neoadjuvant therapy of any kind. Trying to de-escalate a little bit the intensity of treatment that we can provide to the patients in the long run, including combination therapies provided in the adjuvant phase, and particularly trying to identify new strategies that may enable patients to skip radical cystectomy and possibly also chemoradiation...
Yeah, there is clearly a path that is suggested by the patients whenever they refuse to undergo a radical cystectomy after, primarily after a major response, deeper response, almost complete response or near complete response after neoadjuvant therapy of any kind. Trying to de-escalate a little bit the intensity of treatment that we can provide to the patients in the long run, including combination therapies provided in the adjuvant phase, and particularly trying to identify new strategies that may enable patients to skip radical cystectomy and possibly also chemoradiation. In this regard, newly investigated therapies and gemcitabine IDR or Tart-200 is pretty well positioned to become a possible opportunity for this patient population so expanding a little bit beyond the boundaries of our visage and responsive CIS which is currently the FDA label of the drug
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
